RBC Capital Reiterates Outperform Rating on Intra-Cellular Therapies (ITCI), 'We remain buyers'
Tweet Send to a Friend
RBC Capital analyst Brian Abrahams reiterated an Outperform rating and $103.00 price target on Intra-Cellular Therapies (NASDAQ: ITCI).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
